ATE474568T1 - Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs. - Google Patents

Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.

Info

Publication number: ATE474568T1
Authority: AT; Austria
Prior art keywords: bcl; gossypol; cancer; docetaxel; paclitaxel
Prior art date: 2001-05-30

Application number

AT02734614T

Other languages

English (en)

Inventor

Shaomeng Wang

Dajun Yang

Original Assignee

Univ Michigan

Univ Georgetown

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-30

Filing date

2002-05-30

Publication date

2010-08-15

2002-05-30 Application filed by Univ Michigan, Univ Georgetown filed Critical Univ Michigan

2010-08-15 Application granted granted Critical

2010-08-15 Publication of ATE474568T1 publication Critical patent/ATE474568T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
229930012538 Paclitaxel Natural products 0.000 title 1
229960003668 docetaxel Drugs 0.000 title 1
QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
239000011885 synergistic combination Substances 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1
108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 3
102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 3
239000005557 antagonist Substances 0.000 abstract 2
108700000711 bcl-X Proteins 0.000 abstract 2
102000055104 bcl-X Human genes 0.000 abstract 2
150000004548 gossypol derivatives Chemical class 0.000 abstract 2
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 1
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 1
230000002424 anti-apoptotic effect Effects 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Epoxy Compounds (AREA)

AT02734614T 2001-05-30 2002-05-30 Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs. ATE474568T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29398301P	2001-05-30	2001-05-30
PCT/US2002/017206 WO2002097053A2 (en)	2001-05-30	2002-05-30	Small molecule antagonists of bcl2 family proteins

Publications (1)

Publication Number	Publication Date
ATE474568T1 true ATE474568T1 (de)	2010-08-15

Family

ID=31495521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02734614T ATE474568T1 (de)	2001-05-30	2002-05-30	Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.

Country Status (17)

Country	Link
US (1)	US20030008924A1 (de)
EP (1)	EP1474121B1 (de)
JP (1)	JP2005515158A (de)
KR (1)	KR20040108528A (de)
CN (1)	CN1589135A (de)
AT (1)	ATE474568T1 (de)
AU (1)	AU2002305769B2 (de)
CA (1)	CA2449245A1 (de)
DE (1)	DE60237115D1 (de)
ES (1)	ES2349349T3 (de)
IL (1)	IL159110A0 (de)
MX (1)	MXPA03010977A (de)
NO (1)	NO20035301D0 (de)
NZ (1)	NZ529792A (de)
SG (1)	SG157952A1 (de)
WO (1)	WO2002097053A2 (de)
ZA (1)	ZA200309306B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO20023357D0 (no) *	2002-04-19	2002-07-11	Amersham Health As	Blanding
US20070060615A1 (en) *	2003-02-18	2007-03-15	University Of South Florida	Method of Modulating Apoptosis Through Modulation of E2F1
JP2007524633A (ja) *	2003-06-25	2007-08-30	ザバーナムインスティチュート	癌細胞におけるアポトーシスの誘導のための化合物および方法
EP1732529A4 (de) *	2004-03-25	2009-02-25	Univ Michigan	Gossypol kokristalle und ihre verwendung
US7842815B2 (en) *	2004-06-17	2010-11-30	Infinity Pharmaceuticals, Inc.	Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
MXPA06014754A (es)	2004-06-17	2007-06-22	Infinity Pharmaceuticals Inc	Compuestos y metodos para inhibir la interaccion de las proteinas bcl con los componentes de enlace.
US20060144723A1 (en) *	2004-11-02	2006-07-06	Mary Fuller	Device for securing valuables
CA2600797A1 (en) *	2005-03-11	2006-09-21	The Regents Of The University Of Michigan	Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
TWI403320B (zh)	2005-12-16	2013-08-01	Infinity Discovery Inc	用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
JP2009532354A (ja) *	2006-03-30	2009-09-10	ザリージェンツオブザユニバーシティオブミシガン	ゴシポール共結晶の生産方法
EP2012801A4 (de)	2006-04-24	2009-08-05	Gloucester Pharmaceuticals Inc	Gemcitabin-kombinationstherapie
US8957027B2 (en)	2006-06-08	2015-02-17	Celgene Corporation	Deacetylase inhibitor therapy
TWI389895B (zh)	2006-08-21	2013-03-21	Infinity Discovery Inc	抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7857804B2 (en)	2006-09-01	2010-12-28	Mccaffrey Timothy A	Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
US20090030088A1 (en) *	2007-04-20	2009-01-29	Clemson University	Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
WO2009036035A1 (en) *	2007-09-10	2009-03-19	Curis, Inc.	Bcl-2 inhibitors
EP2205088B1 (de) *	2007-10-19	2018-02-21	Burnham Institute for Medical Research	Auf naphthalin basierende hemmer von anti-apoptotischen proteinen
CA2733930A1 (en) *	2008-08-14	2010-02-18	The Uab Research Foundation	Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore
CA2746129A1 (en) *	2008-12-11	2010-06-17	Abraxis Bioscience, Llc	Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
AU2010303324A1 (en) *	2009-10-08	2012-04-05	Sanford-Burnham Medical Research Institute	Apogossypolone derivatives as anticancer agents
NZ605526A (en)	2010-07-12	2015-04-24	Celgene Corp	Romidepsin solid forms and uses thereof
US8859502B2 (en)	2010-09-13	2014-10-14	Celgene Corporation	Therapy for MLL-rearranged leukemia
US8945627B2 (en)	2011-05-05	2015-02-03	Wisconsin Alumni Research Foundation	Micelles for the solubilization of gossypol
US8940737B2 (en) *	2011-10-14	2015-01-27	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2013096051A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794591A1 (de)	2011-12-23	2014-10-29	Novartis AG	Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
US9126980B2 (en)	2011-12-23	2015-09-08	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
BR112014015308A8 (pt)	2011-12-23	2017-06-13	Novartis Ag	compostos para inibição da interação de bcl2 com contrapartes de ligação
EP2794592A1 (de)	2011-12-23	2014-10-29	Novartis AG	Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
AU2013202506B2 (en)	2012-09-07	2015-06-18	Celgene Corporation	Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en)	2012-11-14	2015-08-13	Celgene Corporation	Inhibition of drug resistant cancer cells
NZ630311A (en)	2013-12-27	2016-03-31	Celgene Corp	Romidepsin formulations and uses thereof
WO2015123618A1 (en) *	2014-02-14	2015-08-20	Arizona Board Of Regents For The University Of Arizona	Method for increasing bcl2 gene expression
EP3139942B1 (de)	2014-05-05	2019-12-18	Bioventures, Llc	Zusammensetzungen und verfahren zur hemmung antiapoptotischer bcl-2-proteine als anti-aging-mittel
WO2016014625A1 (en)	2014-07-22	2016-01-28	Board Of Trustees Of The University Of Arkansas	Compositions and methods for selectively depleting senescent cells
CN105884634B (zh) *	2015-01-05	2019-06-04	南开大学	棉酚衍生物和它们的制备,在农药上的应用及抗癌活性
US11098021B2 (en)	2015-08-12	2021-08-24	Memorial Sloan-Kettering Cancer Center	Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
US20180335421A1 (en) *	2015-11-20	2018-11-22	Memorial Sloan-Kettering Cancer Center	Method for screening inhibitors targeting anti-apoptotic survival pathways
KR101904893B1 (ko)	2016-02-18	2018-10-10	연세대학교 산학협력단	폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
WO2017142348A1 (ko) *	2016-02-18	2017-08-24	연세대학교 산학협력단	폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
CN109152933B (zh)	2016-04-21	2022-12-02	生物风险投资有限责任公司	诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN109718377B (zh) *	2017-10-31	2021-03-26	中国科学院脑科学与智能技术卓越创新中心	KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
ES3041854T3 (en)	2018-01-22	2025-11-17	Bioventures Llc	Bcl-2 proteins degraders for cancer treatment
US12084423B2 (en)	2018-05-18	2024-09-10	Bioventures, Llc	Piperlongumine analogues and uses thereof
CN109876145A (zh) *	2019-04-25	2019-06-14	中国科学院化学研究所	醋酸棉酚和化疗药的联合用药物
KR20220034782A (ko)	2019-06-12	2022-03-18	주노 쎄러퓨티크스 인코퍼레이티드	세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
WO2022133030A1 (en)	2020-12-16	2022-06-23	Juno Therapeutics, Inc.	Combination therapy of a cell therapy and a bcl2 inhibitor
CA3241668A1 (en)	2021-12-09	2023-06-15	University Of Florida Research Foundation, Incorporated	Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023220655A1 (en)	2022-05-11	2023-11-16	Celgene Corporation	Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4806568A (en) *	1985-09-12	1989-02-21	Research Corporation	Gossypol derivatives
US5026726A (en) *	1989-12-11	1991-06-25	The University Of New Mexico	Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) *	1990-07-12	1995-01-31	The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services	Gossypol acetic acid for the treatment of cancer
US9002545B2 (en)	2011-01-07	2015-04-07	Wabtec Holding Corp.	Data improvement system and method

2002
- 2002-05-30 WO PCT/US2002/017206 patent/WO2002097053A2/en not_active Ceased
- 2002-05-30 SG SG200601161-3A patent/SG157952A1/en unknown
- 2002-05-30 IL IL15911002A patent/IL159110A0/xx unknown
- 2002-05-30 ES ES02734614T patent/ES2349349T3/es not_active Expired - Lifetime
- 2002-05-30 KR KR10-2003-7015683A patent/KR20040108528A/ko not_active Abandoned
- 2002-05-30 JP JP2003500222A patent/JP2005515158A/ja active Pending
- 2002-05-30 AT AT02734614T patent/ATE474568T1/de not_active IP Right Cessation
- 2002-05-30 AU AU2002305769A patent/AU2002305769B2/en not_active Expired
- 2002-05-30 DE DE60237115T patent/DE60237115D1/de not_active Expired - Lifetime
- 2002-05-30 US US10/158,769 patent/US20030008924A1/en not_active Abandoned
- 2002-05-30 EP EP02734614A patent/EP1474121B1/de not_active Expired - Lifetime
- 2002-05-30 NZ NZ529792A patent/NZ529792A/en not_active IP Right Cessation
- 2002-05-30 MX MXPA03010977A patent/MXPA03010977A/es active IP Right Grant
- 2002-05-30 CN CNA028132998A patent/CN1589135A/zh active Pending
- 2002-05-30 CA CA002449245A patent/CA2449245A1/en not_active Abandoned
2003
- 2003-11-28 NO NO20035301A patent/NO20035301D0/no not_active Application Discontinuation
- 2003-11-28 ZA ZA200309306A patent/ZA200309306B/en unknown

Also Published As

Publication number	Publication date
EP1474121A4 (de)	2006-05-03
ES2349349T3 (es)	2010-12-30
ZA200309306B (de)	2006-07-26
EP1474121B1 (de)	2010-07-21
KR20040108528A (ko)	2004-12-24
IL159110A0 (en)	2004-06-01
EP1474121A2 (de)	2004-11-10
NO20035301D0 (no)	2003-11-28
AU2002305769B2 (en)	2007-07-19
WO2002097053A3 (en)	2004-09-10
CN1589135A (zh)	2005-03-02
DE60237115D1 (de)	2010-09-02
CA2449245A1 (en)	2002-12-05
JP2005515158A (ja)	2005-05-26
NZ529792A (en)	2007-04-27
MXPA03010977A (es)	2005-04-08
US20030008924A1 (en)	2003-01-09
HK1071066A1 (en)	2005-07-08
SG157952A1 (en)	2010-01-29
WO2002097053A2 (en)	2002-12-05

Legal Events

Date	Code	Title	Description
2011-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE474568T1 (de)	2010-08-15	Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
BR112012006252A2 (pt)	2017-05-23	"formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
UA108193C2 (uk)	2015-04-10	Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
BRPI0606891A2 (pt)	2009-07-21	anticorpos dr5 e usos dos mesmos
CY1111263T1 (el)	2015-08-05	Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
PT1347971E (pt)	2006-06-30	Inibidores tiazolilicos de tirosina-cinases da familia tec
DE60031268D1 (de)	2006-11-23	Verfahren und zusammansetzung zur behandlung von krebs
EA200700175A1 (ru)	2007-08-31	Композиции и способы лечения воспалительных заболеваний
WO2001098317A3 (en)	2002-09-26	Alpha-glycosylceramides for treating bacterial and fungal infections
MX2009000285A (es)	2009-06-08	Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
NO20060978L (no)	2006-05-26	Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
ATE526991T1 (de)	2011-10-15	Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE495739T1 (de)	2011-02-15	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60330161D1 (de)	2009-12-31	Rifalazil zur behandlung von infektionen mit clostridium difficile
NO20085147L (no)	2009-02-09	Sammensetning for behandling av motstandsdyktige kreftformer omfattende oridonin
DE602004017871D1 (de)	2009-01-02	Zubereitungen zur behandlung von arthritischen erscheinungen
NO20082862L (no)	2008-08-27	Nye alkylfosfolipidderivater med redusert cytotoksisitet og anvendelse derav
DE60313434D1 (de)	2007-06-06	Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
DE602004005821D1 (de)	2007-05-24	Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
DE60312684D1 (de)	2007-05-03	Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
BRPI0410967A (pt)	2006-07-04	compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
ATE460168T1 (de)	2010-03-15	Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE545421T1 (de)	2012-03-15	Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE602005015329D1 (de)	2009-08-20	Rutheniumkomplexe zur krebsbehandlung
ATE541855T1 (de)	2012-02-15	Weitere kristalline formen von rostafuroxin